[Efficacy of 153Sm-EDTMP in the treatment of prostate cancer with bone metastasis].

Abstract

OBJECTIVE:

To investigate the efficacy of 153Sm-EDTMP in the treatment of bone metastasis of prostate cancer (PCa) by comparison with zoledronic acid.

METHODS:

We assigned 55 PCa patients with bone metastasis to receive 153Sm-EDTMP (n = 31) and zoledronic acid (n = 24), the former injected intravenously at the dose of 37.0 MBq/kg body weight, and the latter administered by slow intravenous drip at 4 mg in 100 ml of 0.9% sodium chloride. We performed 99mTc-MDP bone scan before and 1 -2 months after the treatment.

RESULTS:

The rate of pain relief was 83.9% in the 153Sm-EDTMP group and 58.3% in the zoledronic acid group (P = 0.035), and that of bone metabolism change was 64.5% in the former and 33.3% in the latter (P = 0.022).

CONCLUSION:

153Sm-EDTMP is an ideal agent for the treatment of prostate cancer with bone metastasis.

• Authors: Juan-Yi Feng, Chuang-Qi Wu, Peng Zhang, She-Jiao Wang, Xiang-Hong Zheng
• Journal: Zhonghua nan ke xue = National journal of andrology (Zhonghua Nan Ke Xue) Vol. 18 Issue 11 Pg. 982-5 (Nov 2012) ISSN: 1009-3591 [Print] China
• PMID: 23214246 (Publication Type: Controlled Clinical Trial, Journal Article)

Chemical References

• Diphosphonates
• Imidazoles
• Organometallic Compounds
• Organophosphorus Compounds
• Zoledronic Acid
• samarium Sm-153 lexidronam

Topics

• Aged
• Aged, 80 and over
• Bone Neoplasms (drug therapy, secondary)
• Diphosphonates (therapeutic use)
• Humans
• Imidazoles (therapeutic use)
• Male
• Middle Aged
• Neoplasm Metastasis (drug therapy)
• Organometallic Compounds (therapeutic use)
• Organophosphorus Compounds (therapeutic use)
• Prostatic Neoplasms (drug therapy, pathology)
• Zoledronic Acid